Dr. Jim Tananbaum is the founder and current CEO of the Foresite Capital Management, which is a capital firm that specializes in the sector of healthcare. He has managed to lead more than 21 successful investments in the healthcare companies, including Jazz Pharmaceuticals, Amerigroup Pharmaceuticals, and Amira Pharmaceuticals. Dr. Jim is also the founder of Gel Tex Pharmaceuticals, which was later acquired by Genzyme for a price of 2 billion dollars.
Dr. Jim also worked as the affiliate partner of Prospect Venture I, II, and III. In 1997, Dr. Jim founded Theravance Company, from where he worked as the CEO until 2000. In 1991, Dr. Jim worked as the Senior Product Manager of the Merck Company. As a Product Manager, Dr. Jim Tananbaum was part of the team that was responsible for the repositioning of Prilosec.
According to Forbes, Dr. Jim Tananbaum has continued to run a show in the Midas List for three years in a row. This is contributed by the major healthcare investments that were done by Dr. Jim. These investments include Juno Therapeutics and Intarcia Therapeutics, which became the largest biotech IPO in 2014. Furthermore, Jim Tananbaum is an investor in Aimmune and Puma Biotechnology. Aimmune is an immunotherapy treatment for food allergy. Through his company, Foresite Capital, Dr. Jim has invested eighty million dollars in this area. With 25 years in the medical field, Dr. Jim has established and helped many healthcare franchises grow in all of the segments in the economy of healthcare.
Regarding educational background, Dr. Jim Tananbaum attended Harvard Medical School, from where he received his medical degree. He also attended Harvard Business School and earned a Master Degree in Business Administration. In 1985, Dr. Jim Tananbaum received his B.S and B.S.E.E from Yale University. Apart from being a student at Yale University, Dr. Jim also worked as the member of the board of advisors to the same institution.